NEW YOR LONDON FILE: ARCD:347

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

MBWILSON@FULBRIGHT.COM DIRECT DIAL: 512/536-3035

TELEPHONE: 512/474-5201

MARK B. WILSON PARTNER

INTERNET ADDRESS:

FACSIMILE: 512/536-4598

January 16, 2002

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:

January 16, 2002

Date

Mark B. Wilson

Commissioner for Patents Washington, DC 20231

RE:

SN 09/974,749 "GINSENG BERRY EXTRACTS AND PHARMACEUTICAL COMPOSITIONS FROM GINSENG BERRY FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY" - Chun-Su Yuan (Client Reference: UCHI:840)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C56).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10108736/MBW.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Mark B. Wilson Reg. No. 37,259

MBW/cmb

Encl: as noted

25112617.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chun-Su Yuan

Serial No.: 09/974,749

Filed: October 9, 2001

For: GINSENG BERRY EXTRACTS AND PHARMACEUTICAL COMPOSITIONS FROM GINSENG BERRY FOR THE TREATMENT OF TYPE 2 DIABETES

AND OBESITY

OF CENTER 1600/2002

FEB 1 5 2002

Froup Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: ARCD:347US/MEN

7

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date

below:

January 16, 2002

Date

Mark B.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10108736/MBW.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted

Mark B. Wilson Reg. No. 37,259

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

January 16, 2002